Literature DB >> 21098253

Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.

W Poeppl1, S Tobudic, T Lingscheid, R Plasenzotti, N Kozakowski, A Georgopoulos, H Burgmann.   

Abstract

The activity of fosfomycin was evaluated in an experimental methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis model. Eighteen rats were treated for 4 weeks with 150 mg of fosfomycin/kg of body weight intraperitoneally once daily or with saline placebo. After treatment, animals were euthanized and the infected tibiae were processed for quantitative bacterial culture. Bone cultures were positive for methicillin-resistant S. aureus in all 9 (100%) untreated controls and in 2 of 9 (22.2%) fosfomycin-treated rats. Thus, fosfomycin treatment was significantly more efficacious than placebo. No development of resistance was observed after the 4-week treatment period.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21098253      PMCID： PMC3028784          DOI： 10.1128/AAC.00881-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Antibiotic exposure as a risk factor for emergence of resistance: the influence of concentration.

Authors:  I M Gould; F M MacKenzie
Journal:  Symp Ser Soc Appl Microbiol       Date:  2002

2.  In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model.

Authors:  L B Rice; C T Eliopoulos; J D Yao; G M Eliopoulos; R C Moellering
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

Review 3.  Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.

Authors:  R Dagan; K P Klugman; W A Craig; F Baquero
Journal:  J Antimicrob Chemother       Date:  2001-02       Impact factor: 5.790

4.  Modulatory effect of fosfomycin on acute inflammation in the rat air pouch model.

Authors:  K Morikawa; M Nonaka; Ikuko Torii; S Morikawa
Journal:  Int J Antimicrob Agents       Date:  2003-04       Impact factor: 5.283

5.  Adjuvant fosfomycin medication in chronic osteomyelitis.

Authors:  A Meissner; R Haag; R Rahmanzadeh
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

6.  Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.

Authors:  Sho Takahata; Takashi Ida; Toru Hiraishi; Shiro Sakakibara; Kazunori Maebashi; Shinichi Terada; Tetsuro Muratani; Tetsuro Matsumoto; Chikara Nakahama; Kazunori Tomono
Journal:  Int J Antimicrob Agents       Date:  2010-01-13       Impact factor: 5.283

7.  Bactericidal activity of cefotaxime and fosfomycin in cerebrospinal fluid during the treatment of rabbit meningitis experimentally induced by methicillin-resistant Staphylococcus aureus.

Authors:  A Kazmierczak; A Pechinot; J C Tremeaux; J M Duez; E Kohli; H Portier
Journal:  Infection       Date:  1985       Impact factor: 3.553

8.  Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin.

Authors:  Hiroaki Nakazawa; Yuji Kikuchi; Takashi Honda; Tsukasa Isago; Motohiro Nozaki
Journal:  J Infect Chemother       Date:  2003-12       Impact factor: 2.211

Review 9.  Why fosfomycin trometamol as first line therapy for uncomplicated UTI?

Authors:  G C Schito
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283

10.  In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance.

Authors:  Anna Marchese; Laura Gualco; Eugenio A Debbia; Gian Carlo Schito; Anna Maria Schito
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283
View more
  8 in total

1.  Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats.

Authors:  Tilman Lingscheid; Wolfgang Poeppl; Dominik Bernitzky; Luzia Veletzky; Manuel Kussmann; Roberto Plasenzotti; Heinz Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

2.  Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model.

Authors:  Stéphane Corvec; Ulrika Furustrand Tafin; Bertrand Betrisey; Olivier Borens; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

3.  Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.

Authors:  W Poeppl; S Tobudic; T Lingscheid; R Plasenzotti; N Kozakowski; H Lagler; A Georgopoulos; H Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

4.  Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.

Authors:  Q Mei; Y Ye; Y-L Zhu; J Cheng; X Chang; Y-Y Liu; H-R Li; J-B Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-26       Impact factor: 3.267

5.  High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model.

Authors:  Raluca Mihailescu; Ulrika Furustrand Tafin; Stéphane Corvec; Alessandra Oliva; Bertrand Betrisey; Oliver Borens; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

6.  Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.

Authors:  Alessandra Oliva; Ulrika Furustrand Tafin; Elena Maryka Maiolo; Safaa Jeddari; Bertrand Bétrisey; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

7.  Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  C Garrigós; O Murillo; J Lora-Tamayo; R Verdaguer; F Tubau; C Cabellos; J Cabo; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

8.  Fosfomycin enhances phagocyte-mediated killing of Staphylococcus aureus by extracellular traps and reactive oxygen species.

Authors:  Fengge Shen; Xudong Tang; Wei Cheng; Yang Wang; Chao Wang; Xiaochen Shi; Yanan An; Qiaoli Zhang; Mingyuan Liu; Bo Liu; Lu Yu
Journal:  Sci Rep       Date:  2016-01-18       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.